Resumen de: WO2023091915A1

The disclosed opto-enzymatic analyte physiological sensors exhibit improved bonding or adherence between at least two layers of the sensor, either directly or through an intermediate layer, which provides improved function of the sensor. In certain embodiments, there is bonding or adherence of the enzymatic hydrogel to the target analyte dependent oxygen sensing polymer matrix, either directly or through an intermediate barrier layer, such that changes in the partial pressure of oxygen in the enzymatic hydrogel matrix are rapidly reflected in the partial pressure of oxygen in the oxygen sensing matrix. The sensors provide an implantable, wearable, disposable and ideally low-cost way to continuously sense one or more analytes in the body, such as glucose.

Resumen de: US2023157566A1

Electrochemical Impedance Spectroscopy (EIS) is used in conjunction with continuous glucose monitors and continuous glucose monitoring (CGM) to enable in-vivo sensor calibration. gross (sensor) failure analysis, and intelligent sensor diagnostics and faith detection. An equivalent circuit model is defined, and circuit elements are used to characterize sensor behavior.

Resumen de: US2023157643A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.

Resumen de: US2023157598A1

A method includes monitoring, via a device including an electrochemical cell, an electrical current that is proportional to an impedance of the electrochemical cell, and responsive to determining that the electrical current satisfies a threshold, measuring, via the device, a plurality of impedances of the electrochemical cell corresponding to a plurality of frequencies. The method further includes determining a charge transfer conductance and a solution resistance based on the plurality of impedances at fewer than four of the corresponding plurality of frequencies and determining the presence of electrochemical interference based on the solution resistance and the charge transfer conductance. The method further includes outputting an alert based on the determination of the presence of electrochemical interference.

Resumen de: US2023157783A1

A computer-assisted medical device is configured and used to endoluminally navigate to a location in the gastrointestinal system and there treat certain body lumen wall areas while avoiding other body lumen wall areas. Embodiments ablate the inner mucosal layer and sub-mucosal nerve plexus of the stomach, duodenum and jejunum to effect treatment of insulin resistance and metabolic disorders, such as Type II diabetes (T2D), polycystic ovarian syndrome (PCOS), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), congestive heart failure (CHF) and obstructive sleep apnea (OSA). Various sensors are used to assist a clinical operator to navigate from the mouth through the pyloric sphincter and into and through the duodenum and/or jejunum. Various sensors are used to map and identify portions of the duodenum and/or jejunum. Various lumen wall ablation devices and methods are described. Various post-treatment assessments are described.

Resumen de: US2023158234A1

A method of determining initial insulin dosage range for patients with diabetes includes determining insulin dosage range based upon factors of estimated glomerular filtration rate (eGFR) and body mass index (BMI), and administering such dosage to the patient.

Resumen de: US2023158822A1

A method of fabricating metasurface on skin for blood glucose detection, which relates to a flexible wearable electronic technology in healthcare. The blood glucose detectioncomprises: designing metasurface with a resonant ring structure cell, and building a model by simulating a relationship between blood glucose concentration and electromagnetic absorption property of the metasurface; preparing the metasurface on the skin; scanning the metasurface on the skin under different frequencies electromagnetic wave and acquiring a relationship curve between S-11 parameter and frequency; the change of blood glucose concentration is determined according to the resonant peak frequency shift in the relationship curve based on the model. It realizes the electromagnetic wave metasurface with a good skin biocompatibility, a stable electromagnetic property and a high glucose detection accuracy is directly structured on the skin, moreover, it can directly measure human blood glucose concentration without sampling human blood, realizing real non-invasive human blood glucose detection.

Resumen de: WO2023087672A1

A blood glucose prediction method and device based on optical signal features and metabolic thermal features. The method comprises: acquiring first calibrated blood glucose data (1); collecting and generating first, second, third and fourth optical signals (2); collecting and generating first, second, third, fourth, fifth, sixth and seventh metabolic thermal signals (3); extracting and normalizing human optical signal features to generate first, second and third optical feature data groups (4); extracting and normalizing ambient light signal features to generate fourth optical feature data (5); extracting and normalizing metabolic thermal features to generate first, second, third, fourth, fifth, sixth and seventh metabolic thermal feature data (6); performing feature fusion to generate a first feature vector (7); predicting, on the basis of the floating blood glucose prediction model, floating blood glucose values to generate first floating blood glucose data (8); and generating first predicted blood glucose data according to the sum of the first calibrated blood glucose data and the first floating blood glucose data (9). The blood glucose prediction method and device based on optical signal features and metabolic thermal features can be used to provide a non-invasive blood glucose measurement mechanism.

Resumen de: WO2023088265A1

A blood sugar level obtaining apparatus, a blood sugar level measurement apparatus, and a method. The blood sugar level obtaining apparatus comprises a pressure obtaining module (110), a spectral intensity obtaining module (120), and a result obtaining module (130); the pressure obtaining module (110) is used for obtaining pressure data of a part under test of a user acting on a measurement board in a measurement apparatus; the spectral intensity obtaining module (120) is used for obtaining spectral signal intensity acquired when a spectrometer irradiates the measurement board, wherein the spectral signal intensity and the pressure data are obtained in a same time period; the result obtaining module (130) is used for obtaining a blood sugar level measurement result on the basis of the pressure data and the spectral signal intensity.

Resumen de: GB2613032A

A system and method of calibrating a model used in a device for non-invasive in vivo measurement of an analyte concentration using Raman spectroscopy. The device comprises an optical source for providing an optical signal and an optical detector to receive a Raman scattered optical output. The method (Fig.2) comprises, in response to the laser source being directed to a user’s skin 213, gathering Raman scattered radiation from the user’s skin and based on that, calibrating the model based on reference data and the received Raman spectra over an extended period of days. Once the model is calibrated, storing the model for use. The calibration period can be 14 days or 20 days or between 20 and 28 days. The method may comprise receiving reference data from an invasive blood glucose monitoring device.

Resumen de: EP4183326A1

Method and System for providing a signal from an insulin pump, artificial pancreas, or another insulin delivery device as a source of information for improving the accuracy of a continuous glucose sensor (CGS). The effect of using insulin information to enhance sensor accuracy is most prominent at low blood glucose levels, i.e. in the hypoglycemic range, which is critical for any treatment. A system for providing a filtering/state estimation methodology that may be used to determine a glucose state estimate at time t-τ. The estimation may be extrapolated to some future time t and then the extrapolated value is used to extract the blood glucose component. The blood glucose component of the extrapolation and the output of the CGS are weighted and used to estimate the blood glucose level of a subject.

Resumen de: EP4183331A1

A method includes monitoring, via a device including an electrochemical cell, an electrical current that is proportional to an impedance of the electrochemical cell, and responsive to determining that the electrical current satisfies a threshold, measuring, via the device, a plurality of impedances of the electrochemical cell corresponding to a plurality of frequencies. The method further includes determining a charge transfer conductance and a solution resistance based on the plurality of impedances at fewer than four of the corresponding plurality of frequencies and determining the presence of electrochemical interference based on the solution resistance and the charge transfer conductance. The method further includes outputting an alert based on the determination of the presence of electrochemical interference.

Resumen de: WO2022013140A1

A continuous glucose monitoring (CGM) system is configured to detect a reinserted CGM sensor. The system reads a CGM sensor identifier stored in a CGM sensor unit memory in response to insertion of a CGM sensor into the skin of user. The system compares the identifier to any previously-stored identifiers of previously-inserted CGM sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier is stored and CGM may begin. If the identifier matches a previously- stored identifier, indicating a reinserted sensor, a usage limit corresponding to the stored identifier of the reinserted sensor is then checked to determine whether it has been met. If it has, CGM is halted. If it has not, CGM may continue with the reinserted CGM sensor. Methods of detecting reinsertion and usage limits of a CGM sensor are also provided, as are other aspects.

Resumen de: WO2016161254A1

Methods and systems are disclosed analyzing a glucose level of a person having diabetes. The method, in at least one example, comprises receiving into a computing device a plurality of measured glucose values from a continuous glucose monitoring system coupled to a person having diabetes, analyzing the plurality of measured glucose values with a probability analysis tool on the computing device to determine a glucose threshold (g lc ), and a boundary (g ρ ) glucose value at a probability threshold where the person having diabetes requires at least a predetermined insulin dose, and comparing, with the computing device, the boundary glucose value (g ρ ) to the glucose threshold (g lc ), wherein if the boundary glucose value (g ρ ) is greater than the glucose threshold (g lc ) then the computing device performs an alert on a user interface.

Resumen de: WO2023084453A1

The present invention relates to a method and system for determining risk data (1) concerning injury in a user's foot, for designing and developing customised insoles for the early management of biomechanical alterations in diabetic patients, supported by a telemedicine platform and 15 embedded digital modules with protocols and software applications, for acquiring and integrating patient information by means of commercial specialised electronic devices integrated into the platform and which provided step-by-step assistance to an expert (8) for the smart automated design and remote production of customised therapeutic insoles adapted to the size and morphology of each user with diabetic foot syndrome.

Resumen de: WO2023086232A1

In some examples, a system for monitoring glucose includes processing circuitry and a glucose monitor comprising one or more monitor electrodes and one or more working electrodes, wherein a first chemistry stack is disposed on at least one of the monitor electrode(s) and a second chemistry stack is disposed on at least one of the working electrode(s). The processing circuitry may be configured to measure one or more calibration values of an operating parameter of the monitor electrode(s), retrieve one or more pre-calibration values of the operating parameter of the monitor electrode(s), wherein the pre-calibration value(s) were measured before the calibration value, determine one or more delta values using the calibration value(s) and the pre-calibration value(s), and calibrate glucose values sensed by the working electrode(s) using the delta value(s).

Resumen de: WO2023086980A1

Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.

Resumen de: WO2023086632A1

A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non- transitory memory, and at least one processor communicatively coupled to the non- transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.

Resumen de: WO2023086482A1

A device for delivering medicament to a user is disclosed. The device comprises a reservoir for storing medicament; an infusion catheter fluidly communicating with the reservoir to deliver the medicament into a subcutaneous layer of the user; a pump fluidly communicating with the reservoir and infusion catheter for pumping the medicament from the reservoir though the infusion catheter; an introducer needle movable within the infusion catheter, the introducer needle configured to facilitate (a) insertion of the infusion catheter into a subcutaneous layer of the user and (b) retraction of the introducer needle after insertion of the infusion catheter to enable delivery of medicament through the infusion catheter; and a sensor for continuously monitoring glucose level in the user, wherein the sensor is configured to (a) engage the introducer needle and/or the infusion catheter and (b) simultaneously advance along with the infusion catheter during the insertion into the subcutaneous layer of the user by the introducer needle.

Resumen de: AU2021358022A1

A delivery device for delivering medicament, such as insulin, to a patient includes a housing and a base enclosing an inner cavity. Enclosed within the housing is a reservoir for containing a medicament, a delivery mechanism for delivering the medicament to the patient, and a pump in fluid communication with the reservoir and delivery mechanism. The base has an integrally formed fluid channel covered by a flexible membrane in fluid communication with the reservoir and the delivery mechanism. A peristaltic pump mechanism includes a cam assembly having a plurality of cams and cam follower assembly with a plurality of protrusions to sequentially engaging the flexible membrane to advance the fluid through fluid channel.

Resumen de: AU2023202630A1

Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time.

Resumen de: US2023148920A1

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

Resumen de: AU2023202651A1

The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data.

Resumen de: AU2023202712A1

An encapsulation device system for therapeutic applications such as but not limited to regulating blood glucose. The system may comprise an encapsulation device with a first oxygen sensor integrated inside the device and a second oxygen sensor disposed on an outer surface of the device, wherein the sensors allow for real-time measurements (such as oxygen levels) related to cells (e.g., islet cells, stem cell derived beta cells, etc.) housed in the encapsulation device. The system may also feature an exogenous oxygen delivery system operatively connected to the encapsulation device via a channel, wherein the exogenous oxygen delivery system is adapted to deliver oxygen to the encapsulation device.

Resumen de: US2023154625A1

Method and system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.